For the current quarter Mannkind Corporation (NASDAQ:MNKD) has high EPS estimates of $-0.13 in contradiction of low EPS estimates of $-0.29. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement. Maxim Group maintained the shares of MNKD in report on Friday, September 1 with "Buy" rating.
November 8 investment analysts at HC Wainwright made no change to the stock rating of "Buy" with a current price target of $7.00. H.C. Wainwright maintained the stock with "Buy" rating in Wednesday, November 8 report.
MannKind Corporation (NASDAQ:MNKD) was down -0.93% (-$0.03) to $3.21 and showed a volume of 2.57 mln shares. Finally, Maxim Group reaffirmed a "hold" rating on shares of MannKind Corporation in a report on Wednesday. The total amount of shares outstanding is 115.59 million, giving the company a market capitalization of about 371.04 million. However a year ago for the same quarter the company has reported $0.56 EPS.
MannKind Corporation (NASDAQ:MNKD) last released its quarterly earnings results on Monday, August 7th. In the last earnings report the EPS was $-0.27 with 114.87M shares now outstanding.
In other MannKind Corporation news, Director Kent Kresa purchased 166,600 shares of the firm's stock in a transaction on Friday, October 13th. The stock's last price was higher from the average trading price of 50 days recorded at $76.2 while enlarging the period to 200 trading days, the average price was $68.68. MannKind Corporation had a negative return on equity of 24.93% and a negative net margin of 155.83%. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
A number of large investors have recently bought and sold shares of MNKD.
Maxim Group has given MannKind (NASDAQ:MNKD) shares a new Hold rating in a research note issued to clients on Wednesday morning. The firm's quarterly revenue was down 98.7% compared to the same quarter past year. Bank of New York Mellon Corp lifted its holdings in MannKind Corporation by 30.2% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 588,520 shares of the biopharmaceutical company's stock worth $830,000 after acquiring an additional 98,520 shares in the last quarter. MannKind Corporation has had 13 insider trades in the last 3 months, including 1 open market buys and 12 sells. Institutional investors own 14.59% of the company's stock.
WARNING: This report was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another website, it was copied illegally and reposted in violation of USA & global trademark and copyright legislation.
Consequently Mannkind Corporation (NASDAQ:MNKD)'s weekly and monthly volatility is 10.56%, 11.53% respectively. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Company's product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.